Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 94-9027 phase III pediatric hemophilia A prophylaxis and bleed treatment trial
NL-OMON45210Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Primary endpoints: Number of bleeding events during prophylactic treatment, Pharmacokinetics and 1 more. Started Sep 2013; status: active, not recruiting.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON45210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45210.